Lincoln Pharmaceuticals Recommends 18% Dividend; Reports Q4 FY26 Results
Lincoln Pharmaceuticals recommended an 18% dividend (₹1.80 per share) for FY26. The Board approved audited standalone and consolidated financial results for the quarter and year ending March 31, 2026. Unmodified audit opinions were received for the results.
The dividend recommendation and release of financial results are material events for shareholders and investors, impacting their investment decisions.
The recommendation of an 18% dividend is a positive signal to shareholders, indicating the company's financial health and commitment to returning value.
Lincoln Pharmaceuticals Limited announced the outcome of its Board Meeting held on May 28, 2026. The Board approved the Audited Financial Results for the quarter and year ended March 31, 2026, both on a standalone and consolidated basis. The company reported an unmodified audit opinion on these results.
Additionally, the Board recommended a dividend of 18%, equivalent to ₹1.80 per equity share of face value ₹10, for the financial year ended March 31, 2026. This recommendation is subject to the approval of the members at the upcoming Annual General Meeting (AGM).
Financial highlights for the period were also presented. The company's audited financial results will be available on its website, www.lincolnpharma.com.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.